Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Six hundreds patients with chronic hepatitis B clinically diagnosed as compensated liver
cirrhosis are randomly assigned in a 1:1 ratio. One arm is entecavir alone for 2 years; the
other is entecavir alone for the first 0.5 year, entecavir plus thymosin-α for 1 year,
entecavir for another additional 0.5 year.Patients will be assessed at baseline, at every six
months for blood cell count, liver function test, HBVDNA, AFP, prothrombin time, liver
ultrasonography, and Fibroscan;
Phase:
Phase 4
Details
Lead Sponsor:
Beijing Friendship Hospital
Collaborators:
Beijing 302 Hospital Beijing Ditan Hospital Beijing Tiantan Hospital Beijing YouAn Hospital Fifth Hospital of Shijiazhuang City Huashan Hospital Logistics University of Chinese People's Armed Police Forces Nanfang Hospital of Southern Medical University Peking Union Medical College Hospital Peking University Peking University First Hospital Peking University People's Hospital RenJi Hospital Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Shanghai Public Health Clinical Center Shanghai Zhongshan Hospital Sir Run Run Shaw Hospital Tang-Du Hospital The Affiliated Hospital of Yanbian University The First Affiliated Hospital of Shanxi Medical University Tongji Hospital